CR20210599A - Agonistas del receptor del péptido-1 similar al glucagón - Google Patents

Agonistas del receptor del péptido-1 similar al glucagón

Info

Publication number
CR20210599A
CR20210599A CR20210599A CR20210599A CR20210599A CR 20210599 A CR20210599 A CR 20210599A CR 20210599 A CR20210599 A CR 20210599A CR 20210599 A CR20210599 A CR 20210599A CR 20210599 A CR20210599 A CR 20210599A
Authority
CR
Costa Rica
Prior art keywords
glucagon
peptide
receptor agonists
compound
formula
Prior art date
Application number
CR20210599A
Other languages
English (en)
Inventor
Todd Fields
David Andrew Coates
Fucheng Qu
Joseph Daniel Ho
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210599A publication Critical patent/CR20210599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En una modalidad, la presente invención proporciona un compuesto de la fórmula: o una sal farmacéuticamente aceptable del mismo, y métodos para usar este compuesto en el tratamiento de la diabetes mellitus tipo II.
CR20210599A 2019-06-28 2020-06-19 Agonistas del receptor del péptido-1 similar al glucagón CR20210599A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
US201962904906P 2019-09-24 2019-09-24
PCT/US2020/038617 WO2020263695A1 (en) 2019-06-28 2020-06-19 Glucagon-like peptide 1 receptor agonists

Publications (1)

Publication Number Publication Date
CR20210599A true CR20210599A (es) 2021-12-22

Family

ID=71575804

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210599A CR20210599A (es) 2019-06-28 2020-06-19 Agonistas del receptor del péptido-1 similar al glucagón

Country Status (33)

Country Link
US (3) US11655242B2 (es)
EP (2) EP4302826A3 (es)
JP (1) JP7256300B2 (es)
KR (1) KR102738278B1 (es)
CN (1) CN114008033B (es)
AU (1) AU2020309064B2 (es)
CA (1) CA3144055C (es)
CL (1) CL2021003419A1 (es)
CO (1) CO2021017433A2 (es)
CR (1) CR20210599A (es)
DK (1) DK3989972T3 (es)
DO (1) DOP2021000273A (es)
EC (1) ECSP21093576A (es)
ES (1) ES2970173T3 (es)
FI (1) FI3989972T3 (es)
HR (1) HRP20231586T1 (es)
HU (1) HUE065080T2 (es)
IL (2) IL322973A (es)
JO (1) JOP20210337B1 (es)
LT (1) LT3989972T (es)
MD (1) MD3989972T2 (es)
MX (1) MX2021015328A (es)
MY (1) MY198745A (es)
PE (1) PE20220590A1 (es)
PH (1) PH12021553251A1 (es)
PL (1) PL3989972T3 (es)
PT (1) PT3989972T (es)
RS (1) RS64940B1 (es)
SA (1) SA521431209B1 (es)
SI (1) SI3989972T1 (es)
TW (1) TWI751585B (es)
WO (1) WO2020263695A1 (es)
ZA (1) ZA202109587B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
BR112021020335A2 (pt) 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc Agonistas glp-1r e usos dos mesmos
PE20221040A1 (es) * 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
EP4069686B1 (en) * 2019-12-02 2025-01-22 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
PE20231066A1 (es) 2020-02-07 2023-07-17 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1
JP7836762B2 (ja) * 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
MX2022011349A (es) * 2020-03-18 2022-11-10 Lg Chemical Ltd Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
EP4143183B1 (en) 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
JP7858636B2 (ja) 2020-09-10 2026-05-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CA3200245A1 (en) * 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
MX2023008854A (es) 2021-01-28 2023-10-17 Carmot Therapeutics Inc Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
EP4303215A4 (en) * 2021-04-08 2024-09-18 Lg Chem, Ltd. GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r
EP4334304A1 (en) * 2021-05-03 2024-03-13 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (zh) * 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117355517A (zh) * 2021-05-20 2024-01-05 伊莱利利公司 大环胰高血糖素样肽1受体激动剂
CN115703766B (zh) * 2021-08-10 2025-08-08 天地恒一制药股份有限公司 Glp-1受体激动剂及其用途
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
FI4408840T3 (fi) 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina
EP4412707A1 (en) 2021-10-05 2024-08-14 Astrazeneca AB Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
CA3245508A1 (en) 2022-03-08 2025-01-22 Guangzhou Unirise Pharmaceutical Co., Ltd. BENZO BICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS APPLICATION
WO2023222084A1 (zh) * 2022-05-20 2023-11-23 成都地奥九泓制药厂 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
CN120379988A (zh) * 2022-08-24 2025-07-25 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
KR20250105662A (ko) * 2022-11-11 2025-07-08 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
EP4619098A1 (en) 2022-11-16 2025-09-24 Eli Lilly and Company Glucagon-like peptide 1 receptor agonists
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂，其制备方法和应用
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
CN122055348A (zh) 2023-10-19 2026-05-15 伊莱利利公司 取代的苯乙腈及取代的苯乙酸的制备方法
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053180A1 (en) * 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2018098781A1 (en) * 2016-12-01 2018-06-07 Eli Lilly And Company Pyrrolidinone compounds
CN110325530B (zh) * 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
SG11202011704XA (en) 2018-06-15 2020-12-30 Pfizer Glp-1 receptor agonists and uses thereof
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
BR112021020335A2 (pt) 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc Agonistas glp-1r e usos dos mesmos
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
PE20221040A1 (es) 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
MA57692B1 (fr) 2019-11-15 2025-04-30 Ildong Pharmaceutical Co., Ltd. Agoniste du récepteur glp-1 et son utilisation
EP4069686B1 (en) 2019-12-02 2025-01-22 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
JP7836762B2 (ja) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
MX2022011349A (es) 2020-03-18 2022-11-10 Lg Chemical Ltd Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4143183B1 (en) 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Also Published As

Publication number Publication date
JP2022540044A (ja) 2022-09-14
CN114008033A (zh) 2022-02-01
NZ783212A (en) 2025-03-28
KR102738278B1 (ko) 2024-12-06
PT3989972T (pt) 2023-12-04
CA3144055C (en) 2024-01-02
AU2020309064B2 (en) 2023-08-17
ES2970173T3 (es) 2024-05-27
JOP20210337B1 (ar) 2024-04-18
MX2021015328A (es) 2022-01-18
US20250002482A1 (en) 2025-01-02
TWI751585B (zh) 2022-01-01
LT3989972T (lt) 2023-12-27
SA521431209B1 (ar) 2024-08-05
IL288479B1 (en) 2026-04-01
BR112021023923A2 (pt) 2022-01-25
IL288479A (en) 2022-01-01
US11655242B2 (en) 2023-05-23
US20230250092A1 (en) 2023-08-10
FI3989972T3 (fi) 2024-01-24
EP4302826A3 (en) 2024-04-17
US20200407347A1 (en) 2020-12-31
SI3989972T1 (sl) 2024-01-31
HUE065080T2 (hu) 2024-04-28
CN114008033B (zh) 2025-01-10
KR20220012924A (ko) 2022-02-04
RS64940B1 (sr) 2024-01-31
IL322973A (en) 2025-10-01
MD3989972T2 (ro) 2024-05-31
CL2021003419A1 (es) 2022-09-23
AU2020309064A1 (en) 2022-01-27
WO2020263695A1 (en) 2020-12-30
HRP20231586T1 (hr) 2024-03-15
ECSP21093576A (es) 2022-01-31
PL3989972T3 (pl) 2024-03-25
EP3989972B1 (en) 2023-11-08
ZA202109587B (en) 2024-07-31
CA3144055A1 (en) 2020-12-30
DOP2021000273A (es) 2022-03-15
EP3989972A1 (en) 2022-05-04
EP4302826A2 (en) 2024-01-10
MY198745A (en) 2023-09-21
CO2021017433A2 (es) 2022-04-19
JP7256300B2 (ja) 2023-04-11
PH12021553251A1 (en) 2022-09-05
JOP20210337A1 (ar) 2023-01-30
PE20220590A1 (es) 2022-04-22
TW202115040A (zh) 2021-04-16
DK3989972T3 (da) 2023-12-04

Similar Documents

Publication Publication Date Title
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
DOP2025000110A (es) Agonistas del receptor del péptido-1 similar al glucagón
CO2021000453A2 (es) Compuestos coagonistas de gip/glp1
MX2025005440A (es) Agonistas del receptor del peptido-1 similar al glucagon
AR131857A2 (es) Compuestos co-agonistas de gip y glp-1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
MX2021005724A (es) Tratamiento combinado contra nafld y nash.
MX2021005725A (es) Tratamiento de la obesidad y sus complicaciones.
MX382502B (es) Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
BR112023022851A2 (pt) Agonistas de receptor de peptídeo 1 similares ao glucagon macrocíclico
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
MX381977B (es) Moduladores del receptor de péptido 1 tipo glucagón.
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
ZA202004849B (en) Therapeutic agents for treating restless legs syndrome
AR119173A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
AR125905A1 (es) Agonistas del receptor del péptido-1 similar al glucagón